UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 119

Sortiert nach

An efficient discontinuous Galerkin method for aeroacoustic propagation

International journal for numerical methods in fluids, 2012-07, Vol.69 (9), p.1473-1495

2012

Link zum Volltext

Verfügbarkeit prüfen

Prospective translational study investigating circulating predictors of outcome to first-line pazopanib in patients with metastatic renal cell carcinoma (mRCC)

Annals of oncology, 2017-10, Vol.28 Suppl 6, p.vi18

2017

Link zum Volltext

Verfügbarkeit prüfen

Does dose modification affect efficacy of first-line pazopanib in metastatic renal cell carcinoma?

Annals of oncology, 2017-10, Vol.28 Suppl 6, p.vi20

2017

Link zum Volltext

Verfügbarkeit prüfen

Potent natural killer (NK) and myeloid blood cell remodeling by cabozantinib (Cabo) in pre-treated metastatic renal cell carcinoma (mRCC) patients (pts)

Annals of oncology, 2018-10, Vol.29, p.viii312-viii312

2018

Link zum Volltext

Verfügbarkeit prüfen

Subgroups analysis and circulating biomarkers evaluation of RESORT trial: A randomized phase II study in metastatic renal cell carcinoma (mRCC) patients (pts) to evaluate the efficacy of sorafenib after metastasectomy

Annals of oncology, 2018-10, Vol.29, p.viii311-viii312

2018

Link zum Volltext

Verfügbarkeit prüfen

Prognostic value of systemic inflammatory biomarkers in patients with mCRPC treated with Abiraterone in pre-docetaxel setting

Annals of oncology, 2017-10, Vol.28 Suppl 6, p.vi20

2017

Link zum Volltext

Verfügbarkeit prüfen

Broad immunomodulating effect of first-line Pazopanib in metastatic renal cell carcinoma patients

Annals of oncology, 2017-10, Vol.28 Suppl 6, p.vi17

2017

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of cabozantinib for metastatic renal cell carcinoma (mRCC): real world data from an Italian Expanded Access Program (EAP)

Annals of oncology, 2017-10, Vol.28 Suppl 6, p.vi18

2017

Link zum Volltext

Verfügbarkeit prüfen

Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: A multicenter retrospective analysis

European journal of cancer (1990), 2017-02, Vol.72, p.S190-S190

2017

Link zum Volltext

Verfügbarkeit prüfen

2544 Abiraterone acetate in metastatic castration-resistant prostate cancer after chemotherapy. A retrospective “Real Life” analysis of activity and safety

European journal of cancer (1990), 2015-09, Vol.51, p.S490-S490

2015

Link zum Volltext

Verfügbarkeit prüfen

233TiP Pembrolizumab (pembro) or placebo added to docetaxel and prednisone/prednisolone for metastatic castration-resistant prostate cancer (mCRPC) previously treated with next-generation hormonal agents (NHAs): KEYNOTE-921 phase III study

Annals of oncology, 2020-11, Vol.31, p.S1332-S1333

2020

Link zum Volltext

Verfügbarkeit prüfen

1364MO Preliminary phase II results of the CYPIDES study of ODM-208 in metastatic castration-resistant prostate (mCRPC) cancer patients

Annals of oncology, 2022-09, Vol.33, p.S1165

2022

Link zum Volltext

Verfügbarkeit prüfen

1771MO Pembrolizumab (pembro) plus enzalutamide (enza) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Randomized double-blind phase III KEYNOTE-641 study

Annals of oncology, 2023-10, Vol.34, p.S957-S957

2023

Link zum Volltext

Verfügbarkeit prüfen

1718P A French experience on COVID-19 and cancer from an academic general hospital in Paris area

Annals of oncology, 2020-09, Vol.31, p.S1009-S1009

2020

Link zum Volltext

Verfügbarkeit prüfen

Nivolumab in metastatic renal cell carcinoma (mRCC) patients: a real world single-center experience

Annals of oncology, 2016-09, Vol.27, p.iv30

2016

Link zum Volltext

Verfügbarkeit prüfen

614MO Cabazitaxel (CBZ) activity in men with metastatic castration resistant prostate cancer (mCRPC) with and without DNA damage repair (DDR) defects

Annals of oncology, 2020-09, Vol.31, p.S510-S510

2020

Link zum Volltext

Verfügbarkeit prüfen

Prostate cancer patients with cardiovascular risk factors: long-term safety of abiraterone acetate

Annals of oncology, 2016-09, Vol.27, p.iv35

2016

Link zum Volltext

Verfügbarkeit prüfen

Prognostic value of systemic inflammatory biomarkers in patients with mCRPC treated with abiraterone in pre-docetaxel setting

Annals of oncology, 2017-09, Vol.28, p.v282-v283

2017

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of Cabozantinib for metastatic renal cell carcinoma (mRCC): real world data from an Italian Expanded Access Program (EAP)

Annals of oncology, 2017-09, Vol.28, p.v319-v320

2017

Link zum Volltext

Verfügbarkeit prüfen

Broad immunomodulating effect of first-line pazopanib in metastatic renal cell carcinoma patients

Annals of oncology, 2017-09, Vol.28, p.v315-v315

2017

Link zum Volltext

Verfügbarkeit prüfen

Outcome of patients with multiple glandular metastases from renal cell carcinoma treated with targeted agents

Annals of oncology, 2016-09, Vol.27, p.iv34

2016

Link zum Volltext

Verfügbarkeit prüfen

2175 - Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: A multicenter retrospective analysis

European journal of cancer (1990), 2017-02, Vol.72, p.S190-S190

2017

Link zum Volltext

Verfügbarkeit prüfen

Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy

Drug design, development and therapy, 2016-07, Vol.2016 (Issue 1), p.2167-2172

2016

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 119

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(99)
Mit Volltextzugriff
(106)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(61)
Life Sciences & Biomedicine
(32)
Humans
(27)
Technology
(20)
Hematology
(13)
Biological And Medical Sciences
(11)
Engineering
(11)
Exact Sciences And Technology
(11)
Physical Sciences
(11)
Physics
(11)
Applied Sciences
(9)
Physics, Fluids & Plasmas
(9)
Cells, Cultured
(8)
Immunology
(8)
Medical Sciences
(8)
Condensed Matter Physics
(7)
Engineering, Electrical & Electronic
(7)
Nuclear And High Energy Physics
(7)
Nuclear Fusion
(7)
Nuclear Science & Technology
(7)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

An efficient discontinuous Galerkin method for aeroacoustic propagation

Prospective translational study investigating circulating predictors of outcome to first-line pazopanib in patients with metastatic renal cell carcinoma (mRCC)

Does dose modification affect efficacy of first-line pazopanib in metastatic renal cell carcinoma?

Potent natural killer (NK) and myeloid blood cell remodeling by cabozantinib (Cabo) in pre-treated metastatic renal cell carcinoma (mRCC) patients (pts)

Subgroups analysis and circulating biomarkers evaluation of RESORT trial: A randomized phase II study in metastatic renal cell carcinoma (mRCC) patients (pts) to evaluate the efficacy of sorafenib after metastasectomy

Prognostic value of systemic inflammatory biomarkers in patients with mCRPC treated with Abiraterone in pre-docetaxel setting

Broad immunomodulating effect of first-line Pazopanib in metastatic renal cell carcinoma patients

Safety and efficacy of cabozantinib for metastatic renal cell carcinoma (mRCC): real world data from an Italian Expanded Access Program (EAP)

Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: A multicenter retrospective analysis

2544 Abiraterone acetate in metastatic castration-resistant prostate cancer after chemotherapy. A retrospective “Real Life” analysis of activity and safety

233TiP Pembrolizumab (pembro) or placebo added to docetaxel and prednisone/prednisolone for metastatic castration-resistant prostate cancer (mCRPC) previously treated with next-generation hormonal agents (NHAs): KEYNOTE-921 phase III study

1364MO Preliminary phase II results of the CYPIDES study of ODM-208 in metastatic castration-resistant prostate (mCRPC) cancer patients

1771MO Pembrolizumab (pembro) plus enzalutamide (enza) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Randomized double-blind phase III KEYNOTE-641 study

1808P Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel every 2 weeks (16 mg/m2) versus every 3 weeks (25 mg/m2) in the CABASTY phase III trial

1718P A French experience on COVID-19 and cancer from an academic general hospital in Paris area

673P Cabozantinib-nivolumab (CN) vs. nivolumab-cabozantinib (NC) in patients (pts) with metastatic clear cell renal cell carcinoma (mRCC) following one prior VEGFR tyrosine kinase inhibitor (TKI): The CABIR multicentric matching-adjusted study

Nivolumab in metastatic renal cell carcinoma (mRCC) patients: a real world single-center experience

614MO Cabazitaxel (CBZ) activity in men with metastatic castration resistant prostate cancer (mCRPC) with and without DNA damage repair (DDR) defects

Prostate cancer patients with cardiovascular risk factors: long-term safety of abiraterone acetate

Prognostic value of systemic inflammatory biomarkers in patients with mCRPC treated with abiraterone in pre-docetaxel setting

Safety and efficacy of Cabozantinib for metastatic renal cell carcinoma (mRCC): real world data from an Italian Expanded Access Program (EAP)

Broad immunomodulating effect of first-line pazopanib in metastatic renal cell carcinoma patients

Outcome of patients with multiple glandular metastases from renal cell carcinoma treated with targeted agents

2175 - Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: A multicenter retrospective analysis

Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy

Suchergebnisse filtern